Lumateperone for Bipolar Depression in Teens

Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

Recruiting Phase 3 Interventional Study
Bipolar Depression
Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
10 – 17
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
384 (estimated)
Sponsor
Intra-Cellular Therapies, Inc. · Industry
Who this trial is looking for

This trial is looking for young people aged 10 to 17 who have bipolar depression. Participants will receive either the study medication or a placebo while their mood is monitored.

Are You a Good Fit for This Trial?

You may be able to join if

  • I am between 10 and 17 years old.
  • I have been diagnosed with bipolar I or bipolar II disorder.
  • I have been having a major depressive episode for at least 4 weeks.
  • I have had at least one manic or hypomanic episode in my life.
  • I can give my consent with help from my legal guardian.
  • I show significant depressive symptoms as measured on a specific scale.

You may not be able to join if

  • I have another primary psychiatric diagnosis.
  • I have been hospitalized for a manic episode in the last 30 days.
  • I have had a significant improvement in my depression symptoms before starting.
  • I am at significant risk for suicidal behavior.
  • I have had any suicidal attempts in the last 2 years.
  • I have an intellectual disability.

Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.

Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnosti…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Able to provide consent as follows: * The Legally Authorized Representative (LAR) must provide written, informed consent. * The patient must provide written assent; 2. Male or female patients 10 to 17 years of age, inclusive; 3. Have a Diagnostic and Statistical Manual…
Contacts

Study Contact

844-434-4210

Participate-In-This-Study1@its.jnj.com

CONTACT